专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20080228133A1 DELIVERY OF A SYMPATHOLYTIC CARDIOVASCULAR AGENT TO THE CENTRAL NERVOUS SYSTEM 有权
标题翻译：向中央神经系统递送病理性心脏血管代谢
公开(公告)号：US20080228133A1
公开(公告)日：2008-09-18
申请号：US12128046
申请日：2008-05-28
申请人： KEITH R. HILDEBRAND , Michael R. Ujhelyi , Xiaohong Zhou , Daniel C. Sigg , Linda M. Page
发明人： KEITH R. HILDEBRAND , Michael R. Ujhelyi , Xiaohong Zhou , Daniel C. Sigg , Linda M. Page
IPC分类号： A61M31/00
CPC分类号： A61M5/142 , A61M5/14276 , A61M5/1723 , A61M2005/14208 , A61M2205/3523 , A61M2230/00 , A61M2230/04 , A61M2230/63 , A61N1/3962
摘要： A sympatholytic cardiovascular agent delivered by a drug delivery pump to a central nervous system site to alleviate symptoms of acute or chronic cardiac insult or impaired cardiac performance. The drug delivery pump can be external or implantable infusion pump (IIP) coupled with a drug infusion catheter extending to the site. A patient activator can command delivery of a dosage and/or an implantable heart monitor (IHM) coupled with a sensor can detect physiologic parameters associated with cardiac insult or impaired cardiac performance and trigger dosage delivery. The IIP and IHM can be combined into a single implantable medical device (IMD) or can constitute separate IMDs that communicate by any of known communication mechanisms. The sympatholytic cardiovascular agent is one of the group consisting of an alpha-adrenergic agonist and an alpha2-adrenergic agonist (e.g., clonidine, p-aminoclonidine, guanabenz, lidamidine, tizanidine, moxonidine, methyldopa, xylazine, guanfacine, detomidine, medetomidine, and dexmedetomidine).
摘要翻译：由药物输送泵递送至中枢神经系统部位的交感神经心血管药物以缓解急性或慢性心脏损伤或心脏功能受损的症状。药物输送泵可以是外部或植入式输液泵（IIP），其与延伸到现场的药物输注导管结合。患者活化剂可以命令递送剂量和/或与传感器耦合的可植入心脏监测器（IHM）可以检测与心脏损伤相关的生理参数或心脏功能受损并触发剂量递送。 IIP和IHM可以组合成单个可植入医疗设备（IMD），或者可以构成通过任何已知的通信机制进行通信的单独IMD。交感神经心血管药剂是由α-肾上腺素能激动剂和α2-肾上腺素能激动剂（例如可乐定，对氨基可乐定，胍苯胺，利脒，替扎尼定，莫索尼定，甲基多巴，甲苯噻嗪，胍法西林，美托洛尼，美托咪定和右美托咪定）。

2. 发明授权

US07232435B2 Delivery of a sympatholytic cardiovascular agent to the central nervous system to counter heart failure and pathologies associated with heart failure 有权
标题翻译：向中枢神经系统递送交感神经心血管药物以对抗心力衰竭和与心力衰竭相关的病理
公开(公告)号：US07232435B2
公开(公告)日：2007-06-19
申请号：US10773965
申请日：2004-02-06
申请人： Keith R. Hildebrand , Michael R. Ujhelyi , Xiaohong Zhou , Daniel C. Sigg , Linda M. Page
发明人： Keith R. Hildebrand , Michael R. Ujhelyi , Xiaohong Zhou , Daniel C. Sigg , Linda M. Page
IPC分类号： A61K9/22
CPC分类号： A61M5/142 , A61M5/14276 , A61M5/1723 , A61M2005/14208 , A61M2205/3523 , A61M2230/00 , A61M2230/04 , A61M2230/63 , A61N1/3962
摘要： A sympatholytic cardiovascular agent delivered by a drug delivery pump to a central nervous system site to alleviate symptoms and otherwise treat heart failure (HF) and pathologies associated with HF. The drug delivery pump can be external or implantable infusion pump (IIP) coupled with a drug infusion catheter extending to the site. A patient activator can command delivery of a dosage and/or an implantable heart monitor (IHM) coupled with a sensor can detect physiologic parameters associated with HF (or pathologies associated with HF) and trigger dosage delivery. The IIP and IHM can be combined into a single implantable medical device (IMD) or can constitute separate IMDs that communicate by any of known communication mechanisms. The sympatholytic cardiovascular agent is one of the group consisting of an alpha-adrenergic agonist and an alpha2-adrenergic agonist, e.g., clonidine, p-aminoclonidine, guanabenz, lidamidine, tizanidine, moxonidine, methyldopa, xylazine, guanfacine, detomidine, medetomidine, and dexmedetomidine.
摘要翻译：由药物输送泵递送至中枢神经系统部位的交感神经心血管药物以缓解症状，另外治疗与HF有关的心力衰竭（HF）和病理学。药物输送泵可以是外部或植入式输液泵（IIP），其与延伸到现场的药物输注导管结合。患者活化剂可以命令递送剂量和/或与传感器耦合的可植入心脏监测器（IHM）可以检测与HF相关的生理学参数（或与HF相关的病理学）和触发剂量递送。 IIP和IHM可以组合成单个可植入医疗设备（IMD），或者可以构成通过任何已知的通信机制进行通信的单独IMD。交感神经心血管药物是由α-肾上腺素能激动剂和α2-肾上腺素能激动剂组成的组之一，例如可乐定，对氨基可乐定，胍苯胺，利脒，替扎尼定，莫西康定，甲基多巴，甲苯噻嗪，胍法辛，右美托咪定。

3. 发明授权

US07390311B2 Delivery of a sympatholytic cardiovascular agent to the central nervous system 有权
标题翻译：交配性心血管药物向中枢神经系统递送
公开(公告)号：US07390311B2
公开(公告)日：2008-06-24
申请号：US10903599
申请日：2004-07-30
申请人： Keith R. Hildebrand , Michael R. Ujhelyi , Xiaohong Zhou , Daniel C. Sigg , Linda M. Page
发明人： Keith R. Hildebrand , Michael R. Ujhelyi , Xiaohong Zhou , Daniel C. Sigg , Linda M. Page
IPC分类号： A61M31/00
CPC分类号： A61M5/142 , A61M5/14276 , A61M5/1723 , A61M2005/14208 , A61M2205/3523 , A61M2230/00 , A61M2230/04 , A61M2230/63 , A61N1/3962
摘要： A sympatholytic cardiovascular agent delivered by a drug delivery pump to a central nervous system site to alleviate symptoms of acute or chronic cardiac insult or impaired cardiac performance. The drug delivery pump can be external or implantable infusion pump (IIP) coupled with a drug infusion catheter extending to the site. A patient activator can command delivery of a dosage and/or an implantable heart monitor (IHM) coupled with a sensor can detect physiologic parameters associated with cardiac insult or impaired cardiac performance and trigger dosage delivery. The IIP and IHM can be combined into a single implantable medical device (IMD) or can constitute separate IMDs that communicate by any of known communication mechanisms. The sympatholytic cardiovascular agent is one of the group consisting of an alpha-adrenergic agonist and an alpha2-adrenergic agonist (e.g., clonidine, p-aminoclonidine, guanabenz, lidamidine, tizanidine, moxonidine, methyldopa, xylazine, guanfacine, detomidine, medetomidine, and dexmedetomidine).
摘要翻译：由药物输送泵递送至中枢神经系统部位的交感神经心血管药物以缓解急性或慢性心脏损伤或心脏功能受损的症状。药物输送泵可以是外部或植入式输液泵（IIP），其与延伸到现场的药物输注导管结合。患者活化剂可以命令递送剂量和/或与传感器耦合的可植入心脏监测器（IHM）可以检测与心脏损伤相关的生理参数或心脏功能受损并触发剂量递送。 IIP和IHM可以组合成单个可植入医疗设备（IMD），或者可以构成通过任何已知的通信机制进行通信的单独IMD。交感神经心血管药物是由α-肾上腺素能激动剂和α2-肾上腺素能激动剂（例如可乐定，对氨基可乐定，胍苯胺，利脒，替扎尼定，莫索尼定，甲基多巴，甲苯噻嗪，胍法西汀，脱甲基丸，美托咪定和右美托咪定）。

4. 发明授权

US08348884B2 Delivery of a sympatholytic cardiovascular agent to the central nervous system 有权
标题翻译：交配性心血管药物向中枢神经系统递送
公开(公告)号：US08348884B2
公开(公告)日：2013-01-08
申请号：US12128046
申请日：2008-05-28
申请人： Keith R. Hildebrand , Michael R. Ujhelyi , Xiaohong Zhou , Daniel C. Sigg , Linda M. Page
发明人： Keith R. Hildebrand , Michael R. Ujhelyi , Xiaohong Zhou , Daniel C. Sigg , Linda M. Page
IPC分类号： A61M31/00
CPC分类号： A61M5/142 , A61M5/14276 , A61M5/1723 , A61M2005/14208 , A61M2205/3523 , A61M2230/00 , A61M2230/04 , A61M2230/63 , A61N1/3962
摘要： A sympatholytic cardiovascular agent delivered by a drug delivery pump to a central nervous system site to alleviate symptoms of acute or chronic cardiac insult or impaired cardiac performance. The drug delivery pump can be external or implantable infusion pump (IIP) coupled with a drug infusion catheter extending to the site. A patient activator can command delivery of a dosage and/or an implantable heart monitor (IHM) coupled with a sensor can detect physiologic parameters associated with cardiac insult or impaired cardiac performance and trigger dosage delivery. The IIP and IHM can be combined into a single implantable medical device (IMD) or can constitute separate IMDs that communicate by any of known communication mechanisms. The sympatholytic cardiovascular agent is one of the group consisting of an alpha-adrenergic agonist and an alpha2-adrenergic agonist (e.g., clonidine, p-aminoclonidine, guanabenz, lidamidine, tizanidine, moxonidine, methyldopa, xylazine, guanfacine, detomidine, medetomidine, and dexmedetomidine).
摘要翻译：由药物输送泵递送至中枢神经系统部位的交感神经心血管药物以缓解急性或慢性心脏损伤或心脏功能受损的症状。药物输送泵可以是外部或植入式输液泵（IIP），其与延伸到现场的药物输注导管结合。患者活化剂可以命令递送剂量和/或与传感器耦合的可植入心脏监测器（IHM）可以检测与心脏损伤相关的生理参数或心脏功能受损并触发剂量递送。 IIP和IHM可以组合成单个可植入医疗设备（IMD），或者可以构成通过任何已知的通信机制进行通信的单独IMD。交感神经心血管药物是由α-肾上腺素能激动剂和α2-肾上腺素能激动剂（例如可乐定，对氨基可乐定，胍苯胺，利脒，替扎尼定，莫索尼定，甲基多巴，甲苯噻嗪，胍法西汀，脱甲基丸，美托咪定和右美托咪定）。

5. 发明授权

US09775987B2 Implantable medical device crosstalk evaluation and mitigation 有权
公开(公告)号：US09775987B2
公开(公告)日：2017-10-03
申请号：US12362792
申请日：2009-01-30
申请人： William T. Donofrio , John E. Burnes , Paul G. Krause , Gerald P. Arne , David J. Peichel , Xiaohong Zhou , James D. Reinke , Timothy Davis
发明人： William T. Donofrio , John E. Burnes , Paul G. Krause , Gerald P. Arne , David J. Peichel , Xiaohong Zhou , James D. Reinke , Timothy Davis
IPC分类号： A61N1/00 , A61N1/05 , A61N1/36 , A61N1/37 , A61N1/372 , A61N1/39 , A61N1/362 , A61N1/365 , A61N1/08
CPC分类号： A61N1/0551 , A61N1/36114 , A61N1/3621 , A61N1/36521 , A61N1/37 , A61N1/37247 , A61N1/37282 , A61N1/3962 , A61N2001/083
摘要： Electrical crosstalk between two implantable medical devices or two different therapy modules of a common implantable medical device may be evaluated, and, in some examples, mitigated. In some examples, one of the implantable medical devices or therapy modules delivers electrical stimulation to a nonmyocardial tissue site or a nonvascular cardiac tissue site, and the other implantable medical device or therapy module delivers cardiac rhythm management therapy to a heart of the patient.

6. 发明授权

US09192769B2 Shunt-current reduction techniques for an implantable therapy system 有权
标题翻译：用于植入式治疗系统的分流电流还原技术
公开(公告)号：US09192769B2
公开(公告)日：2015-11-24
申请号：US12551331
申请日：2009-08-31
申请人： William T. Donofrio , John E. Burnes , Paul G. Krause , Gerald P. Arne , Xiaohong Zhou
发明人： William T. Donofrio , John E. Burnes , Paul G. Krause , Gerald P. Arne , Xiaohong Zhou
IPC分类号： A61N1/08 , A61N1/37 , A61N1/36 , A61N1/372
CPC分类号： A61N1/3718 , A61N1/08 , A61N1/086 , A61N1/36114 , A61N1/37288
摘要： Techniques for minimizing interference between the first and second medical devices or between the different therapy modules of a common medical device are described herein. In some examples, a medical device may include shunt-current mitigation circuitry and/or at least one clamping structure that helps minimize or even eliminate shunt-current that feeds into a first therapy module of the medical device via one or more electrodes electrically connected to the first therapy module. The shunt-current may be generated by the delivery of electrical stimulation by a second therapy module. The second therapy module may be enclosed in a common housing with the first therapy module or may be separate, e.g., a part of a separate medical device.
摘要翻译：本文描述了用于最小化第一和第二医疗装置之间或在普通医疗装置的不同治疗模块之间的干扰的技术。在一些示例中，医疗装置可以包括分流电流缓解电路和/或至少一个夹持结构，其有助于最小化或甚至消除通过电连接到医疗装置的一个或多个电极馈入医疗装置的第一治疗模块的分流电流第一疗法模块。分流电流可以通过第二治疗模块的电刺激递送来产生。第二治疗模块可以用第一治疗模块封闭在共同的壳体中，或者可以是分离的，例如单独的医疗装置的一部分。

7. 发明授权

US08725259B2 Vagal stimulation 有权
公开(公告)号：US08725259B2
公开(公告)日：2014-05-13
申请号：US13353861
申请日：2012-01-19
申请人： Lilian Kornet , Richard N. M. Cornelussen , Paul D. Ziegler , Xiaohong Zhou , Eduardo Warman , Karen J. Kleckner , Lucy Nichols , Alberto Della Scala
发明人： Lilian Kornet , Richard N. M. Cornelussen , Paul D. Ziegler , Xiaohong Zhou , Eduardo Warman , Karen J. Kleckner , Lucy Nichols , Alberto Della Scala
IPC分类号： A61N1/365
CPC分类号： A61N1/36114
摘要： The disclosure herein relates generally to methods for treating heart conditions using vagal stimulation, and further to systems and devices for performing such treatment. Such methods may include monitoring physiological parameters of a patient, detecting cardiac conditions, and delivering vagal stimulation (e.g., electrical stimulation to the vagus nerve or neurons having parasympathetic function) to the patient to treat the detected cardiac conditions.

8. 发明申请

US20130060150A1 METHOD AND APPARATUS FOR MONITORING CARDIAC AND RESPIRATORY CONDITIONS USING ACOUSTIC SOUNDS 审中-公开
标题翻译：使用声音监测心脏和呼吸系统状况的方法和装置
公开(公告)号：US20130060150A1
公开(公告)日：2013-03-07
申请号：US13456357
申请日：2012-04-26
申请人： Zhendong Song , Xiaohong Zhou
发明人： Zhendong Song , Xiaohong Zhou
IPC分类号： A61B5/0205 , A61B7/00 , A61B5/08
CPC分类号： A61B7/003 , A61B5/02 , A61B5/0205 , A61B5/0826 , A61B7/00 , A61N1/3627 , A61N1/36514
摘要： A medical device system and associated method discriminating conditions that includes a plurality of sensors, a sensing module coupled to the plurality of sensors and configured to acquire signals from the plurality of sensors, and a processor coupled to the sensing module and configured to determine a change in a respiratory related sounds in response to a signal from a sensor of the plurality of sensors, select one or more sensors of the plurality of sensors associated with the determined change, determine a respiratory signature in response to signals from the selected one or more sensors, and determine the respiratory condition in response to the determined respiratory signature.
摘要翻译：一种医疗设备系统和相关联的方法来区分包括多个传感器的条件，耦合到多个传感器并被配置为从多个传感器获取信号的感测模块以及耦合到感测模块并被配置为确定变化的处理器在响应于来自多个传感器的传感器的信号的呼吸相关声音中，选择与所确定的变化相关联的多个传感器中的一个或多个传感器，响应于来自所选择的一个或多个传感器的信号来确定呼吸特征并且响应于所确定的呼吸标志来确定呼吸状况。

9. 发明申请

US20130060149A1 METHOD AND APPARATUS FOR MONITORING CARDIAC AND RESPIRATORY CONDITIONS USING ACOUSTIC SOUNDS 审中-公开
标题翻译：使用声音监测心脏和呼吸道条件的方法和装置
公开(公告)号：US20130060149A1
公开(公告)日：2013-03-07
申请号：US13456346
申请日：2012-04-26
申请人： Zhendong Song , Xiaohong Zhou
发明人： Zhendong Song , Xiaohong Zhou
IPC分类号： A61B7/00 , A61B5/0205
摘要： A medical device system and associated method discriminate respiratory and cardiac conditions using respiratory sounds. A sensing module acquires a first signal and a second signal, at least the second signal acquired from an acoustic transducer. A processor is configured to receive the first signal and to control the sensing module to acquire the second acoustic signal in response to a change in the first signal. The processor discriminates between a cardiac condition and a respiratory condition as a cause of the change in the first signal in response to the second acoustic signal.
摘要翻译：医疗设备系统和相关方法使用呼吸音来辨别呼吸和心脏病状。感测模块至少从声换能器获取的第二信号获取第一信号和第二信号。处理器被配置为接收第一信号并且响应于第一信号的改变来控制感测模块获取第二声信号。处理器根据第二声信号，将心脏状况与呼吸状况鉴别为第一信号的变化的原因。

10. 发明授权

US08260412B2 Implantable medical device crosstalk evaluation and mitigation 有权
公开(公告)号：US08260412B2
公开(公告)日：2012-09-04
申请号：US12362809
申请日：2009-01-30
申请人： Paul G. Krause , John E. Burnes , William T. Donofrio , David J. Peichel , Gerald P. Arne , Xiaohong Zhou , James D. Reinke , Timothy Davis
发明人： Paul G. Krause , John E. Burnes , William T. Donofrio , David J. Peichel , Gerald P. Arne , Xiaohong Zhou , James D. Reinke , Timothy Davis
IPC分类号： A61N1/00
CPC分类号： A61N1/3622 , A61N1/36114 , A61N1/36185 , A61N1/3686 , A61N1/3688
摘要： Electrical crosstalk between two implantable medical devices or two different therapy modules of a common implantable medical device may be evaluated, and, in some examples, mitigated. In some examples, one of the implantable medical devices or therapy modules delivers electrical stimulation to a nonmyocardial tissue site or a nonvascular cardiac tissue site, and the other implantable medical device or therapy module delivers cardiac rhythm management therapy to a heart of the patient.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式